pegaptanib sodium
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Macugen | — | 2006-01-31 | europa.eu ↗ |
| Approved | US (FDA) | MACUGEN | — | 2004-09-17 | fda.gov ↗ |
Trials 34 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT00242580 Comparator | Sep 2005 → Jan 2008 | age-related macular degeneration, choroidal neovascularization | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT02321267 Background | Dec 2014 → Dec 2024 | macular degeneration | Kagawa University | Unknown | No outcome recorded |
| Phase 4 | NCT00406107 Comparator | Jan 2006 → Dec 2007 | occlusion of tributary of retinal vein | Palmetto Retina Center, LLC | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01218230 Comparator | Dec 2010 → Jul 2012 | choroidal neovascularization | L.V. Prasad Eye Institute | Withdrawn | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 43 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pegaptanib sodium | “Eligible participants with ischaemic diabetic macular oedema will receive an intravitreal injection of pegaptanib sodium (Macugen \[TM\]) 0.3mg every 6 weeks over a 30 week period.” NCT01175070 ↗19“OBJECTIVES: To assess the safety and efficacy of intravitreous pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO).” PMID 19365011 ↗ Apr 2009 “An open-label, one-year, noncomparative study to evaluate the safety and tolerability of intravitreal pegaptanib sodium in patients with diabetic macular edema.” PMID 25187694 ↗ Aug 2014 “Pegaptanib sodium is an aptamer designed to bind the VEGF 165 isoform with high affinity.” NCT00531336 ↗ “Intravitreous Injections of Pegaptanib sodium (Anti-VEGF Pegylated Aptamer)” NCT00312351 ↗ “Pegaptanib Sodium (Macugen®), Given As Often As Every 6 Weeks for 2 Years” NCT00605280 ↗ “Macugen ™ (pegaptanib sodium injection)” NCT00087763 ↗ “Macugen ® (pegaptanib sodium)” NCT01486771 ↗ “pegaptanib sodium (Macugen)” NCT00215670 ↗ “pegaptanib sodium (Macugen)” NCT00406107 ↗ “Macugen (Pegaptanib Sodium)” NCT01487070 ↗ “Macugen (Pegaptanib Sodium)” NCT01487044 ↗ “Macugen (pegaptanib sodium)” NCT00272766 ↗ “pegaptanib sodium (Macugen)” NCT00040313 ↗ “pegaptanib sodium (Macugen)” NCT00324116 ↗ “pegaptanib sodium (Macugen)” NCT00354445 ↗ “Macugen (pegaptanib sodium)” NCT00134667 ↗ “Drug: Pegaptanib sodium” NCT00346983 ↗ |
| Known as | 0.3mg Pegaptanib Sodium, Macugen | “0.3mg Pegaptanib Sodium, Macugen” NCT01589718 ↗ |
| Known as | EYE001 | “Intravitreal Injections of EYE001 (Anti-VEGF Pegylated Aptamer)” NCT00040313 ↗ |
| Known as | EYEOO1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201421 ↗ |
| Known as | Macugen | “Effect of pegaptanib sodium 0.3 mg intravitreal injections (Macugen) in intraocular pressure: posthoc analysis from V.I.S.I.O.N. study.” PMID 24997182 ↗ Jul 201415“The substances currently in clinical use include ranibizumab (Lucentis®), bevacizumab (Avastin®) and pegaptanib (Macugen®).” NCT00709657 ↗ “Pegaptanib Sodium (Macugen®), Given As Often As Every 6 Weeks for 2 Years” NCT00605280 ↗ “Macugen ™ (pegaptanib sodium injection)” NCT00087763 ↗ “pegaptanib (also called Macugen)” NCT00358423 ↗ “Macugen ® (pegaptanib sodium)” NCT01486771 ↗ “Macugen (pegaptanib sodium)” NCT00272766 ↗ “pegaptanib sodium (Macugen)” NCT00215670 ↗ “Macugen (Pegaptanib Sodium)” NCT01487070 ↗ “Macugen (Pegaptanib Sodium)” NCT01487044 ↗ “pegaptanib sodium (Macugen)” NCT00040313 ↗ “pegaptanib sodium (Macugen)” NCT00354445 ↗ “Macugen (pegaptanib sodium)” NCT00134667 ↗ “Pegaptanib (Macugen)” NCT00531336 ↗ |
| Known as | Macugen \[TM\] | “Eligible participants with ischaemic diabetic macular oedema will receive an intravitreal injection of pegaptanib sodium (Macugen \[TM\]) 0.3mg every 6 weeks over a 30 week period.” NCT01175070 ↗ |
| Known as | NX-1838 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201421 ↗ |
| Known as | pegaptanib | “intravitreous pegaptanib 0.3 mg or sham injection.” PMID 21896838 ↗ Sep 201132“Macugen (pegaptanib)” NCT00446381 ↗ |
| Known as | Pegaptanib na | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201421 ↗ |
| Action | Inhibit | “anti-VEGF drug” NCT00021736 ↗ |
| Modality | Aptamer | “EYE001 anti-VEGF aptamer” NCT00021736 ↗ |
| Route | Intravitreal | “Intravitreal Injections of EYE001” NCT00021736 ↗ |
| Target | VEGF | “EYE001 decreases production of VEGF” NCT00056199 ↗ |